AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

BK Technologies Corp. (BKTI) â€� Schedule 13G/A (Amendment 1)

The filing discloses that investor Mikhail Stiskin, through his wholly-owned entities Hilve Holdings Ltd. (Cyprus) and Valdor Global DMCC (UAE), now beneficially owns 253,164 BKTI common shares, or 6.9 % of the 3,673,594 shares outstanding as of 8 May 2025. Ownership is held entirely with sole voting and dispositive power; no shares are held jointly.

Breakdown: Hilve Holdings directly holds 220,833 shares (6.0 %); Valdor Global DMCC holds 32,331 shares (0.9 %). The positions exceed the 5 % threshold that triggers a passive Schedule 13G filing, indicating the shares were acquired without intent to influence control of the issuer. The date of the reportable event is 30 Jun 2025, and signatures are dated 5 Aug 2025.

No financial metrics, purchase prices, or transaction dates beyond the ownership snapshot are provided. The filing simply updates beneficial ownership and does not announce any corporate action, change-in-control effort, or strategic agreement.

BK Technologies Corp. (BKTI) � Modifica al Schedule 13G/A (Emendamento 1)

La comunicazione rivela che l'investitore Mikhail Stiskin, tramite le sue entità interamente controllate Hilve Holdings Ltd. (Cipro) e Valdor Global DMCC (EAU), detiene ora la proprietà beneficiaria di 253.164 azioni ordinarie BKTI, pari al 6,9% delle 3.673.594 azioni in circolazione al 8 maggio 2025. La proprietà è detenuta interamente con pieno potere di voto e di disposizione; nessuna azione è detenuta congiuntamente.

Dettaglio: Hilve Holdings detiene direttamente 220.833 azioni (6,0%); Valdor Global DMCC detiene 32.331 azioni (0,9%). Le posizioni superano la soglia del 5% che determina la presentazione di un Schedule 13G passivo, indicando che le azioni sono state acquisite senza intenzione di influenzare il controllo dell’emittente. La data dell’evento segnalabile è il 30 giugno 2025, mentre le firme sono datate 5 agosto 2025.

Non sono forniti dati finanziari, prezzi di acquisto o date delle transazioni oltre all’istantanea della proprietà. La comunicazione aggiorna semplicemente la proprietà beneficiaria e non annuncia alcuna azione societaria, tentativo di cambio di controllo o accordo strategico.

BK Technologies Corp. (BKTI) � Programación 13G/A (Enmienda 1)

La presentación revela que el inversor Mikhail Stiskin, a través de sus entidades de propiedad total Hilve Holdings Ltd. (Chipre) y Valdor Global DMCC (EAU), posee ahora 253,164 acciones ordinarias BKTI, o el 6.9% de las 3,673,594 acciones en circulación al 8 de mayo de 2025. La propiedad se mantiene totalmente con poder exclusivo de voto y disposición; no hay acciones en copropiedad.

Desglose: Hilve Holdings posee directamente 220,833 acciones (6.0%); Valdor Global DMCC posee 32,331 acciones (0.9%). Las posiciones superan el umbral del 5% que obliga a una presentación pasiva de Schedule 13G, indicando que las acciones fueron adquiridas sin intención de influir en el control del emisor. La fecha del evento reportable es el 30 de junio de 2025, y las firmas están fechadas el 5 de agosto de 2025.

No se proporcionan métricas financieras, precios de compra ni fechas de transacciones más allá de la instantánea de propiedad. La presentación simplemente actualiza la propiedad beneficiaria y no anuncia ninguna acción corporativa, esfuerzo de cambio de control o acuerdo estratégico.

BK Technologies Corp. (BKTI) � Schedule 13G/A (수정 1)

ì‹ ê³ ì„œì— ë”°ë¥´ë©� 투ìžìž� Mikhail Stiskinì€ ì „ì•¡ 소유í•� ë²•ì¸ Hilve Holdings Ltd. (키프로스)와 Valdor Global DMCC (UAE)ë¥� 통해 253,164 BKTI 보통ì£�ë¥� 보유하고 있으ë©�, ì´ëŠ” 2025ë…� 5ì›� 8ì� 기준 ë°œí–‰ì£¼ì‹ ì´ìˆ˜ 3,673,594ì£¼ì˜ 6.9%ì—� 해당합니ë‹�. ì†Œìœ ê¶Œì€ ì „ì ìœ¼ë¡œ ë‹¨ë… ì˜ê²°ê¶� ë°� 처분ê¶�ì� 가지ê³� 있으ë©� ê³µë™ ë³´ìœ  주ì‹ì€ 없습니다.

세부 ë‚´ì—­: Hilve HoldingsëŠ� ì§ì ‘ 220,833ì£� (6.0%)ë¥�, Valdor Global DMCCëŠ� 32,331ì£� (0.9%)ë¥� 보유하고 있습니다. ì� ì§€ë¶„ì€ 5% ì´ìƒì� 기준ì� 초과하여 수ë™ì � Schedule 13G 제출 대ìƒì´ë©�, ì´ëŠ” ë°œí–‰ì‚¬ì˜ ì§€ë°°ê¶Œì—� ì˜í–¥ì� 미칠 ì˜ë„ ì—†ì´ ì£¼ì‹ì� ì·¨ë“í–ˆìŒì� 나타냅니ë‹�. ë³´ê³  가능한 사건 ë°œìƒì¼ì€ 2025ë…� 6ì›� 30ì¼ì´ë©�, 서명ì¼ì€ 2025ë…� 8ì›� 5ì¼ìž…니다.

재무 ì§€í‘�, 매입 ê°€ê²� ë˜ëŠ” 소유ê¶� 현황 ì™¸ì˜ ê±°ëž˜ ë‚ ì§œëŠ� 제공ë˜ì§€ 않았습니ë‹�. ì� ì œì¶œì€ ë‹¨ìˆœíž� 실소유권ì� ì—…ë°ì´íЏí•� 것으ë¡�, 기업 활ë™, 지배권 ë³€ê²� ì‹œë„ ë˜ëŠ” ì „ëžµì � í•©ì˜ë¥� 발표하지 않습니다.

BK Technologies Corp. (BKTI) � Déclaration Schedule 13G/A (Amendement 1)

Le dépôt révèle que l'investisseur Mikhail Stiskin, par l'intermédiaire de ses entités entièrement détenues Hilve Holdings Ltd. (Chypre) et Valdor Global DMCC (EAU), détient désormais 253 164 actions ordinaires BKTI, soit 6,9 % des 3 673 594 actions en circulation au 8 mai 2025. La propriété est détenue entièrement avec le pouvoir exclusif de vote et de disposition ; aucune action n'est détenue conjointement.

Répartition : Hilve Holdings détient directement 220 833 actions (6,0 %) ; Valdor Global DMCC détient 32 331 actions (0,9 %). Les positions dépassent le seuil de 5 % qui déclenche un dépôt passif Schedule 13G, indiquant que les actions ont été acquises sans intention d'influencer le contrôle de l'émetteur. La date de l'événement déclarable est le 30 juin 2025, et les signatures datent du 5 août 2025.

Aucune donnée financière, prix d'achat ou date de transaction au-delà du pointage de propriété n'est fournie. Le dépôt met simplement à jour la propriété bénéficiaire et n'annonce aucune action corporative, tentative de changement de contrôle ou accord stratégique.

BK Technologies Corp. (BKTI) � Schedule 13G/A (Änderung 1)

Die Einreichung offenbart, dass der Investor Mikhail Stiskin über seine vollständig im Besitz befindlichen Gesellschaften Hilve Holdings Ltd. (Zypern) und Valdor Global DMCC (VAE) nun wirtschaftlich 253.164 BKTI-Stammaktien besitzt, was 6,9 % der 3.673.594 ausstehenden Aktien zum 8. Mai 2025 entspricht. Das Eigentum wird vollständig mit alleinigem Stimm- und Verfügungsrecht gehalten; keine Aktien werden gemeinsam gehalten.

Aufschlüsselung: Hilve Holdings hält direkt 220.833 Aktien (6,0 %); Valdor Global DMCC hält 32.331 Aktien (0,9 %). Die Positionen überschreiten die 5%-Schwelle, die eine passive Schedule 13G-Meldung auslöst, was darauf hinweist, dass die Aktien ohne Absicht zur Einflussnahme auf die Kontrolle des Emittenten erworben wurden. Das melderelevante Ereignisdatum ist der 30. Juni 2025, die Unterschriften sind auf den 5. August 2025 datiert.

Es werden keine finanziellen Kennzahlen, Kaufpreise oder Transaktionsdaten über den Eigentumsstand hinaus angegeben. Die Einreichung aktualisiert lediglich die wirtschaftliche Eigentümerschaft und kündigt keine Unternehmensmaßnahme, Kontrollwechselversuch oder strategische Vereinbarung an.

Positive
  • Experienced investor adds 6.9 % stake, signalling confidence in BKTI’s prospects without activist pressure.
  • All shares held with sole voting power, simplifying future governance disclosures.
Negative
  • Ownership concentration rises; a single holder now controls nearly 7 % of the float, potentially impacting liquidity.
  • Lack of disclosure on acquisition price or intentions offers limited insight into valuation thesis.

Insights

TL;DR: Disclosure of a 6.9 % passive stake by Mikhail Stiskin; limited direct impact on BKTI operations.

This amendment shows Stiskin accumulating just under 7 % of BKTI through two offshore entities. Because the stake is filed under Schedule 13G rather than 13D, the investor certifies no activist intent. For a micro-cap (�3.7 m shares outstanding), any 5 %+ holder can affect liquidity and voting dynamics, but the absence of control ambitions suggests neutral-to-slightly-positive sentiment: a sophisticated investor is willing to build a meaningful position. There is no information about purchase cost, financing sources, or future plans, so valuation impact should be minimal unless Stiskin later converts to an activist stance (would require a 13D).

BK Technologies Corp. (BKTI) � Modifica al Schedule 13G/A (Emendamento 1)

La comunicazione rivela che l'investitore Mikhail Stiskin, tramite le sue entità interamente controllate Hilve Holdings Ltd. (Cipro) e Valdor Global DMCC (EAU), detiene ora la proprietà beneficiaria di 253.164 azioni ordinarie BKTI, pari al 6,9% delle 3.673.594 azioni in circolazione al 8 maggio 2025. La proprietà è detenuta interamente con pieno potere di voto e di disposizione; nessuna azione è detenuta congiuntamente.

Dettaglio: Hilve Holdings detiene direttamente 220.833 azioni (6,0%); Valdor Global DMCC detiene 32.331 azioni (0,9%). Le posizioni superano la soglia del 5% che determina la presentazione di un Schedule 13G passivo, indicando che le azioni sono state acquisite senza intenzione di influenzare il controllo dell’emittente. La data dell’evento segnalabile è il 30 giugno 2025, mentre le firme sono datate 5 agosto 2025.

Non sono forniti dati finanziari, prezzi di acquisto o date delle transazioni oltre all’istantanea della proprietà. La comunicazione aggiorna semplicemente la proprietà beneficiaria e non annuncia alcuna azione societaria, tentativo di cambio di controllo o accordo strategico.

BK Technologies Corp. (BKTI) � Programación 13G/A (Enmienda 1)

La presentación revela que el inversor Mikhail Stiskin, a través de sus entidades de propiedad total Hilve Holdings Ltd. (Chipre) y Valdor Global DMCC (EAU), posee ahora 253,164 acciones ordinarias BKTI, o el 6.9% de las 3,673,594 acciones en circulación al 8 de mayo de 2025. La propiedad se mantiene totalmente con poder exclusivo de voto y disposición; no hay acciones en copropiedad.

Desglose: Hilve Holdings posee directamente 220,833 acciones (6.0%); Valdor Global DMCC posee 32,331 acciones (0.9%). Las posiciones superan el umbral del 5% que obliga a una presentación pasiva de Schedule 13G, indicando que las acciones fueron adquiridas sin intención de influir en el control del emisor. La fecha del evento reportable es el 30 de junio de 2025, y las firmas están fechadas el 5 de agosto de 2025.

No se proporcionan métricas financieras, precios de compra ni fechas de transacciones más allá de la instantánea de propiedad. La presentación simplemente actualiza la propiedad beneficiaria y no anuncia ninguna acción corporativa, esfuerzo de cambio de control o acuerdo estratégico.

BK Technologies Corp. (BKTI) � Schedule 13G/A (수정 1)

ì‹ ê³ ì„œì— ë”°ë¥´ë©� 투ìžìž� Mikhail Stiskinì€ ì „ì•¡ 소유í•� ë²•ì¸ Hilve Holdings Ltd. (키프로스)와 Valdor Global DMCC (UAE)ë¥� 통해 253,164 BKTI 보통ì£�ë¥� 보유하고 있으ë©�, ì´ëŠ” 2025ë…� 5ì›� 8ì� 기준 ë°œí–‰ì£¼ì‹ ì´ìˆ˜ 3,673,594ì£¼ì˜ 6.9%ì—� 해당합니ë‹�. ì†Œìœ ê¶Œì€ ì „ì ìœ¼ë¡œ ë‹¨ë… ì˜ê²°ê¶� ë°� 처분ê¶�ì� 가지ê³� 있으ë©� ê³µë™ ë³´ìœ  주ì‹ì€ 없습니다.

세부 ë‚´ì—­: Hilve HoldingsëŠ� ì§ì ‘ 220,833ì£� (6.0%)ë¥�, Valdor Global DMCCëŠ� 32,331ì£� (0.9%)ë¥� 보유하고 있습니다. ì� ì§€ë¶„ì€ 5% ì´ìƒì� 기준ì� 초과하여 수ë™ì � Schedule 13G 제출 대ìƒì´ë©�, ì´ëŠ” ë°œí–‰ì‚¬ì˜ ì§€ë°°ê¶Œì—� ì˜í–¥ì� 미칠 ì˜ë„ ì—†ì´ ì£¼ì‹ì� ì·¨ë“í–ˆìŒì� 나타냅니ë‹�. ë³´ê³  가능한 사건 ë°œìƒì¼ì€ 2025ë…� 6ì›� 30ì¼ì´ë©�, 서명ì¼ì€ 2025ë…� 8ì›� 5ì¼ìž…니다.

재무 ì§€í‘�, 매입 ê°€ê²� ë˜ëŠ” 소유ê¶� 현황 ì™¸ì˜ ê±°ëž˜ ë‚ ì§œëŠ� 제공ë˜ì§€ 않았습니ë‹�. ì� ì œì¶œì€ ë‹¨ìˆœíž� 실소유권ì� ì—…ë°ì´íЏí•� 것으ë¡�, 기업 활ë™, 지배권 ë³€ê²� ì‹œë„ ë˜ëŠ” ì „ëžµì � í•©ì˜ë¥� 발표하지 않습니다.

BK Technologies Corp. (BKTI) � Déclaration Schedule 13G/A (Amendement 1)

Le dépôt révèle que l'investisseur Mikhail Stiskin, par l'intermédiaire de ses entités entièrement détenues Hilve Holdings Ltd. (Chypre) et Valdor Global DMCC (EAU), détient désormais 253 164 actions ordinaires BKTI, soit 6,9 % des 3 673 594 actions en circulation au 8 mai 2025. La propriété est détenue entièrement avec le pouvoir exclusif de vote et de disposition ; aucune action n'est détenue conjointement.

Répartition : Hilve Holdings détient directement 220 833 actions (6,0 %) ; Valdor Global DMCC détient 32 331 actions (0,9 %). Les positions dépassent le seuil de 5 % qui déclenche un dépôt passif Schedule 13G, indiquant que les actions ont été acquises sans intention d'influencer le contrôle de l'émetteur. La date de l'événement déclarable est le 30 juin 2025, et les signatures datent du 5 août 2025.

Aucune donnée financière, prix d'achat ou date de transaction au-delà du pointage de propriété n'est fournie. Le dépôt met simplement à jour la propriété bénéficiaire et n'annonce aucune action corporative, tentative de changement de contrôle ou accord stratégique.

BK Technologies Corp. (BKTI) � Schedule 13G/A (Änderung 1)

Die Einreichung offenbart, dass der Investor Mikhail Stiskin über seine vollständig im Besitz befindlichen Gesellschaften Hilve Holdings Ltd. (Zypern) und Valdor Global DMCC (VAE) nun wirtschaftlich 253.164 BKTI-Stammaktien besitzt, was 6,9 % der 3.673.594 ausstehenden Aktien zum 8. Mai 2025 entspricht. Das Eigentum wird vollständig mit alleinigem Stimm- und Verfügungsrecht gehalten; keine Aktien werden gemeinsam gehalten.

Aufschlüsselung: Hilve Holdings hält direkt 220.833 Aktien (6,0 %); Valdor Global DMCC hält 32.331 Aktien (0,9 %). Die Positionen überschreiten die 5%-Schwelle, die eine passive Schedule 13G-Meldung auslöst, was darauf hinweist, dass die Aktien ohne Absicht zur Einflussnahme auf die Kontrolle des Emittenten erworben wurden. Das melderelevante Ereignisdatum ist der 30. Juni 2025, die Unterschriften sind auf den 5. August 2025 datiert.

Es werden keine finanziellen Kennzahlen, Kaufpreise oder Transaktionsdaten über den Eigentumsstand hinaus angegeben. Die Einreichung aktualisiert lediglich die wirtschaftliche Eigentümerschaft und kündigt keine Unternehmensmaßnahme, Kontrollwechselversuch oder strategische Vereinbarung an.

0001845337false00018453372025-08-052025-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2025

 

 

DAY ONE BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

001-40431

83-2415215

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1800 Sierra Point Parkway, Suite 200

 

Brisbane, California

 

94005

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (650) 484-0899

 

 

N/A

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

DAWN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On August 5, 2025, Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. A copy of the Company’s presentation with respect to its financial results for the quarter ended June 30, 2025 is attached as Exhibit 99.2 to this report.

Item 7.01 Regulation FD Disclosure.

On August 5, 2025, the Company updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.3 to this report.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

 

 

 

Exhibit

Number

Description

 

 

99.1

Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter ended June 30, 2025, dated August 5, 2025.

 

 

 

99.2

 

Financial Results Presentation.

 

 

 

99.3

 

Corporate Presentation.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

DAY ONE BIOPHARMACEUTICALS, INC.

 

 

 

 

Date:

August 5, 2025

By:

/s/ Charles N. York II, M.B.A.

 

 

 

Charles N. York II, M.B.A.
Chief Operating Officer and Chief Financial Officer

 


FAQ

Who is the new 5 %+ shareholder of BKTI disclosed in the Schedule 13G/A?

Mikhail Stiskin, via Hilve Holdings Ltd. and Valdor Global DMCC, now beneficially owns 6.9 % of BK Technologies.

How many BKTI shares does Hilve Holdings Limited own?

Hilve Holdings holds 220,833 common shares, representing 6.0 % of outstanding shares.

Does the filing indicate activist intent?

No. It is a Schedule 13G, which certifies the shares were acquired without intent to influence control of the issuer.

What is the total outstanding share count used for the ownership calculation?

The percentages are based on 3,673,594 shares outstanding as reported by BKTI on 13 May 2025.

When did the reportable ownership event occur?

The triggering event date is 30 June 2025; signatures are dated 5 August 2025.
Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

DAWN Latest News

DAWN Latest SEC Filings

DAWN Stock Data

697.37M
84.03M
17.05%
94.82%
10.14%
Biotechnology
Pharmaceutical Preparations
United States
BRISBANE